default author photo

Chee Wah Tan

SingHealth Duke-NUS Global Health Institute

SCHOLARLY PAPERS

4

DOWNLOADS

349

TOTAL CITATIONS

1

Scholarly Papers (4)

1.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne, Flinders University, University of Melbourne, University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 127 (569,079)

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

2.

Preclinical Evaluation of a Cross-Protective ß-SARS-CoV-2 Virus-Like Particle Vaccine Adjuvanted with MF59

Number of pages: 52 Posted: 26 Mar 2024
University of Melbourne - Department of Microbiology and Immunology (DMI), University of New South Wales (UNSW), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), La Trobe University - Department of Biochemistry & Chemistry, The Walter and Eliza Hall Institute of Medical Research, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Royal Melbourne Hospital, SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI) and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 119 (604,538)

Abstract:

Loading...

SARS-CoV-2, COVID-19 variants, vaccine, virus-like particles, VLP, receptor-binding domain, RBD

3.

Longitudinal Analysis of Neutralizing Antibodies Against SARS-CoV-1 and Different SARS-CoV-2 Strains in Breakthrough and Unvaccinated Covid-19 Patients in Thailand

Number of pages: 39 Posted: 29 Jun 2024
Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies, Prachatipat Hospital, Prachatipat Hospital, Vichaivej International Hospital, Vichaivej International Hospital, Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies, Hospital of Tropical Diseases - Oxford University Clinical Research Unit, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University - Institute of Human Righs and Peace Studies and Mahidol University - Institute of Human Righs and Peace Studies
Downloads 76 (830,555)
Citation 1

Abstract:

Loading...

COVID-19, neutralizing antibody, SARS-CoV-1, SARS-CoV-2, variants, vaccination

4.

Immunogenicity of IndoVac, a Domestically Manufactured SARS-CoV-2 Protein Subunit Ancestral-strain Vaccine, as a Fifth-dose Booster, Compared with Prior mRNA Vaccine Boosters: A Longitudinal Cohort Study in Indonesian Healthcare Workers

Number of pages: 36 Posted: 18 Mar 2026
Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), University of Indonesia (UI) - Faculty of Medicine, St. Carolus Hospital, St. Carolus Hospital, Universitas Indonesia (UI), SingHealth Duke-NUS Global Health Institute, Hospital of Tropical Diseases - Oxford University Clinical Research Unit, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, Universitas Indonesia (UI), Universitas Indonesia (UI) and Independent
Downloads 27 (1,359,097)

Abstract:

Loading...

COVID-19, SARS-CoV-2, heterologous vaccine booster, IndoVac, mRNA vaccine, protein subunit vaccine